Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Latest Press Releases
First Phase III Clinical Trial results of Safinamide in Advanced Parkinson's disease to be presented at the Movement Disorder Society's 13th International Congress03/06/2009 | 
ENG
| 
GER
| |
Newron Reports Initiation of SETTLE, the Second Phase III Clinical Trial of Safinamide in Advanced Parkinson's Disease07/05/2009 |
ENG
|
GER
|
Investor News
Please click here to view Newron share price information on SIX.
